Banzel

Drugs - Banzel® (rufinamide) [Eisai Inc]

November 2016

Therapeutic area - Antiepileptic

Approval criteria

• Patient has a diagnosis of Lennox-Gastaut Syndrome AND
• Patient has tried and failed THREE or more anti-epileptic drugs which include: clonazepam, valproate, lamotrigine or topiramate OR
• Prescriber is a neurologist AND patient has tried and failed at least TWO anti-epileptic drugs which include: clonazepam, valproate, lamotrigine or topiramate

Quantity limits

• 200 mg tablets:  544 tablets per 34 days 
• 400 mg tablets:  480 tablets per 34 days
• Oral suspension (40 mg/mL):  2720 mL per 34 days

Background information

BANZEL (rufinamide) is FDA-approved for the adjunctive treatment of seizures associated with Lennox-Gastault Syndrome in patients one year of age and older. Patients taking BANZEL should be monitored for changes in mood, behavior or personality that are atypical for the patient.

Questions?

MHCP Provider Call Center 651-431-2700 or 800-366-5411